Skip to main content
Premium Trial:

Request an Annual Quote

Illumina to Offer $800M in Convertible Senior Notes

By a GenomeWeb Staff Reporter

NEW YORK (GenomeWeb News) – Illumina today priced an offering of $800 million in convertible senior notes due 2016.

The notes will pay interest semi-annually at a rate of .25 percent. They are convertible upon certain conditions, and upon conversion, holders will receive cash, shares of the firm's common stock, or a combination of both, based on an initial conversion rate of 11.9687 shares of common stock per $1,000 principal amount of the notes — equal to an initial conversion price of roughly $83.55 per share.

The San Diego-based firm also has granted initial purchasers a 30-day option to purchase up to $120 million of additional notes.

Up to $425 million in net proceeds from the offering will be used by the company to buy back shares of its common stock in privately negotiated deals concurrent with the offering. Between $260 million and $390 million of net proceeds are being targeted to fund conversions of its currently outstanding convertible notes, Illumina said. The remainder of the funds will be used for general corporate purposes, which may include acquisitions and additional share buybacks.

Illumina expects to close the offering on Friday.

The Scan

Should've Been Spotted Sooner

Scientists tell the Guardian that SARS-CoV-2 testing issues at a UK lab should have been noticed earlier.

For Martian Fuel

Researchers have outlined a plan to produce rocket fuel on Mars that uses a combination of sunlight, carbon dioxide, frozen water, cyanobacteria, and engineered E. coli, according to Gizmodo.

To Boost Rapid Testing

The Washington Post writes that new US programs aim to boost the availability of rapid at-home SARS-CoV-2 tests.

PNAS Papers on Strawberry Evolution, Cell Cycle Regulators, False-Positive Triplex Gene Editing

In PNAS this week: strawberry pan-genome, cell cycle-related roles for MDM2 and MDMX, and more.